Explosive Volume Breakout StocksHello Traders! Today’s session was packed with action as several midcap names showed explosive breakouts on record volumes. These setups are not only backed by price action but also confirmed by multiple technical indicators such as RSI, Bollinger Bands, SuperTrend, VWAP, and BB Squeeze. Let’s decode them in detail 👇
1️ Greenpanel Industries Ltd (NSE: GREENPANEL)
CMP: ₹322.15 (+18.09%)
Breakout with Heavy Volumes
Key Supports: ₹288 / ₹254
Resistances: ₹341 / ₹361 / ₹395
🔑 Strong 52-week breakout with bullish follow-through. Sustaining above ₹288 could keep the momentum alive.
The stock witnessed a 52-week volume breakout, supported by a strong bullish candle that confirms aggressive buying interest. The RSI has broken out, highlighting fresh momentum, while the Bollinger Band breakout shows volatility expansion after a period of consolidation. Alongside this, the Bullish SuperTrend and VWAP indicators confirm trend alignment with volume, suggesting institutional participation. Interestingly, the BB Squeeze turning off signals that the low-volatility phase has ended, and the stock may now enter a trending move.
________________________________________
2️ Indoco Remedies Ltd (NSE: INDOCO)
CMP: ₹308.60 (+11.47%)
RSI Breakout + Volume Expansion
Key Supports: ₹280 / ₹252
Resistances: ₹334 / ₹360 / ₹388
🔑 Open = Low + strong bullish candle. Short-term traders may keep an eye on ₹280 as support.
Indoco Remedies also recorded a powerful 52-week volume breakout, signaling accumulation at higher levels. The RSI breakout validates the momentum shift, while the “open = low” pattern reflects intraday buying from the very start of the session. The Bollinger Band breakout points to volatility expansion, and the Bullish SuperTrend along with VWAP confirms that both trend and volume are favoring the bulls. Additionally, the BB Squeeze compression breakout shows that the stock has just moved out of a tight consolidation, opening the doors for a strong upside continuation.
________________________________________
3️ Piccadilly Agro Industries Ltd (NSE: PICCADIL)
CMP: ₹723.80 (-13.58%)
Strong Bullish Candle on Massive Volumes
Key Supports: ₹660 / ₹598
Resistances: ₹765 / ₹806 / ₹869
🔑 Despite closing off highs, volumes indicate institutional interest. Watch ₹660 as a key level.
Piccadilly Agro displayed a strong bullish candle backed by exceptional volumes, which suggests fresh interest from market participants. The RSI breakout supports the strength of the momentum, while the Bollinger Band breakout indicates that the stock has entered a new volatility phase. Both Bullish SuperTrend and VWAP confirm that the price move is well-supported by trend-following and volume-based systems. With the BB Squeeze off, the compression phase has ended, further confirming the possibility of an extended rally if key supports hold.
________________________________________
4️ SMS Pharmaceuticals Ltd (NSE: SMSPHARMA)
CMP: ₹300.55 (+12.14%)
52-Week Volume Breakout
Key Supports: ₹273 / ₹247
Resistances: ₹319 / ₹339 / ₹365
🔑 Stock showing bullish momentum with multiple indicator confirmations. A close above ₹319 may trigger the next leg.
SMS Pharma registered a 52-week volume breakout combined with short-term bullish momentum, indicating a strong change in trend. The RSI breakout highlights renewed momentum, and the Bollinger Band expansion reflects volatility returning after consolidation. The Bullish SuperTrend and VWAP are both in sync with the buyers, suggesting sustainable strength. The BB Squeeze turning off is another confirmation that the quiet phase is over, and the stock could witness directional movement. Overall, multiple indicators align to suggest that this breakout has solid backing from both price and volume action.
________________________________________
💡 Technical Takeaway:
When volume expansion aligns with RSI, Bollinger Bands, and SuperTrend confirmations, breakouts have higher chances of sustaining. Always track key support levels for validation.
⚠️ Disclaimer – Please Read Carefully
The information shared here is meant purely for learning and awareness. It is not a buy or sell recommendation and should not be taken as investment advice. I am not a SEBI-registered investment advisor, and all views expressed are based on personal study, chart patterns, and publicly available market data.
Trading — whether in stocks or options — carries risk. Markets can move unexpectedly, and losses can sometimes exceed the money you have invested. Past performance or past setups do not guarantee future results.
If you are a beginner, treat this as a guide to understand how the market works — practice on paper trades before risking real money. If you are experienced, always assess your own risk, position sizing, and strategy suitability before entering trades.
Consult a SEBI-registered financial advisor before making any real trading decision. By engaging with this content, you acknowledge full responsibility for your trades and investments.
💬 Found this useful?
🔼 Give this post a Boost to help more traders discover clean, structured learning.
✍️ Drop your thoughts, questions, or setups in the comments — let’s grow together!
🔁 Share with fellow traders and beginners to spread awareness.
👉 “If you liked this breakdown, follow for more clean, structured setups with discipline at the core.”
🚀 Stay Calm. Stay Clean. Trade With Patience.
Trade Smart | Learn Zones | Be Self-Reliant 📊
INDOCO
INDOCO | Positional Trade📊 DETAILS
Sector: Pharmaceuticals & Drugs
Mkt Cap: 3,746 cr
Indoco Remedies (Indoco) is a Mumbai-based pharmaceutical company that focuses on formulations with a presence in contract manufacturing and research. The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).
TTM PE : 33.03 (Average PE)
Sector PE : 51.38
Beta : 0.64
📚 INSIGHTS
Mid-range performer
Stock with medium financial performance with average price momentum and valuation. These stocks may be affordable and are showing some investors interest.
2.04% away from 52 week high
Outperformer - Indoco Remedies up by 7.17% v/s NIFTY 50 up by 1.99% in last 1 month
📈 FINANCIALS
Piotroski Score of 5/9 indicates Average Financials
Disclaimer: This analysis is for educational purposes only, and I'm not a SEBI registered analyst.
If you found this analysis helpful, I encourage you to like and share it. Your observations and comments are also welcomed below. Your support, likes, follows, and comments motivate me to consistently share valuable insights with you.
🔍 More Analysis & Trade Setups 🔍
For more technical analysis and trade setups, make sure to follow me on TradingView: www.tradingview.com
Indoco Remedies Ltd |A Sector Rotation (Pharmaceutical)Indoco Remedies Ltd |A Sector Rotation (Pharmaceutical)
Indoco Remedies (Indoco) is a Mumbai-based pharmaceutical company that focuses on formulations with a presence in contract manufacturing and research.
Market Cap = ₹ 3,758 Cr. Dividend Yield=0.55 % ROCE=17.4 %
ROE =14.8 % Debt to equity = 0.46 Promoter holding = 58.7 %
Quick ratio = 1.13 Current ratio = 1.76 Piotroski score = 5.00
Profit Var 3Yrs = 80.6 % Sales growth 3Years = 14.7 %
Pledged percentage = 0.00 % Return on assets = 9.11 %
Indoco Remedies Limited
is now in momentum zone
I just analyses chart and as per my view I shared my entry exit and tgt
please do your research before investing.
if you like my idea than like and boost and follow me for more ideas.
thanks.
INDOCO review: up till now, from 345 to 394, & yet more to comereviewing NSE:INDOCO chart posted on 11th Aug 2023 when the price was 345
thereafter it made high of 404.70 and now trading at 394 giving excellent 14% gains till now
more gains to come in coming months
This analysis is being done for educational and knowledge-sharing purposes.
This article does not offer any kind of buy or sell advice.
All stocks are positional and are held for a short to medium period of time.
Everyone is expected to conduct their own research and analysis to determine whether my point of view align with your study.
link of 11th Aug 2023 post given below
INDOCO REMEDIES LTDINDOCO:- Trendline breakout with good volume. good for short term. keep on eye
Hello traders,
As always, simple and neat charts so everyone can understand and not make it too complicated.
rest details mentioned in the chart.
will be posting more such ideas like this. Until that, like share and follow :)
check my other ideas to get to know about all the successful trades based on price action.
Thanks,
Ajay.
keep learning and keep earning.
INDOCO REMEDIES LTD _ ADD TO WATCHLISTIndoco Remedies Ltd falling rally may come to end in upcoming weeks. keep concentrate for breakout where upward or downward. Both targets are mentioned in above chart. Confirm breakout in day open closing above or below the trend line. Its good for swing traders.
INDOCO REMEDIES - Medium Term StudyChart Structure:
- Broken out All-Time High (of 2015), pulled back, consolidated a bit, and now ready to go up.
- Price in an uptrend since July 2020.
Volume:
- High volume deliveries this week. Up to 12.41 lac shares were delivered yesterday, whereas average deliveries are 1.23 lacs.
- Yesterday saw the highest delivery of shares in recent times.
Relative Strength:
- Stock become RS+ on 19th April and continuously outperforming Nifty as well as Midcap since then.
- Spread chart breakout happened yesterday.
Financial Highlights:
- Net Revenues saw 29.3% jump in QoQ & 43% YoY.
- PAT increased by 59% QoQ & 130% YoY.
- Co. is continuously increasing its revenues & profits at a medium pace, which tells us the financial health of the company is sound.
- Indoco's Defensive & Enterprises EPS are also been positive throughout the years, which tells us that the company is able to sustain itself without taking any more debts & they are able to monetize their current expenditures for next few years.
About Indoco:
About Indoco Remedies Limited:
Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with a presence in 55 countries. Indoco, a USD 166 million Company, employs over 6000 people including more than 300 skilled scientists.
The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from over 3,00,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments. Indoco has tie-ups with large generic companies across the globe.